BHR to demonstrate EKF Quo-Test HbA1c analyser at Heart UK's conference

POCT offers cost effective convenience and improved patient experience

EKF Diagnostics, the global in vitro diagnostics business, announces today that the Quo-Test, its glycated haemoglobin (HbA1c) analyser for near-patient monitoring of diabetes will be on show at Heart UK. Due to the strong correlation between diabetes and cardiovascular disease, this convenient and cost effective POC analyser will be demonstrated by BHR on Stand 4 at Heart UK’s annual conference in Bristol, 3rd-5th July 2013.

HbA1c monitoring is increasingly used in the detection and management of diabetes. Quo-Test has been designed to provide rapid and reliable measurement of HbA1c at the point-of-care. Having lab-accurate results in just four minutes from 4μL of venous or finger prick blood enables clinicians to make immediate decisions for a patient’s diabetes management. This can result in improved diabetic control, better patient outcomes and enhanced clinic efficiency, with fewer patient visits and subsequent economic benefits.

Quo-Test is CE marked, fully automated and easy to use with intuitive step by step onscreen instructions minimising training time. This compact analyser also ensures efficient data handling, with a barcode reader included and storage of up to 7,000 results, which can be downloaded to a LIS via its USB port. These results are unaffected by haemoglobin variants since Quo-Test uses the well-documented boronate affinity method, which is recognised as interference free.

To be exhibited alongside Quo-Test on BHR’s stand will be other point-of care testing analysers also delivering cost effective convenience and an enhanced patient experience. These products include the CardioChek™ PA blood analyser, the world’s first portable direct LDL cholesterol test and the RAMP 200 CVD analyser, a rapid, quantitative immunochromatographic system for performing in vitro diagnostic analyses on a variety of analytes.

“We are pleased to support Heart UK again this year, working together to improve healthcare and reduce heart disease,” said Andrew Greaves, BHR Sales Director. “Due to the evident link between diabetes and heart disease, EKF Diagnostics’ Quo-Test is an ideal analyser to showcase at this event since it delivers easy and reliable measurement of HbA1c used for the detection and management of diabetes at the point-of-care.”


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
You might also like... ×
Reducing Anemia in Developing Regions with Point of Care Analysis